UY28111A1 - Nueva forma de dosificación oral de liberación inmediata - Google Patents
Nueva forma de dosificación oral de liberación inmediataInfo
- Publication number
- UY28111A1 UY28111A1 UY28111A UY28111A UY28111A1 UY 28111 A1 UY28111 A1 UY 28111A1 UY 28111 A UY28111 A UY 28111A UY 28111 A UY28111 A UY 28111A UY 28111 A1 UY28111 A1 UY 28111A1
- Authority
- UY
- Uruguay
- Prior art keywords
- dosage form
- immediate release
- release dosage
- new oral
- oral immediate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención describe una forma sólida de dosificación oral de liberación inmediata de un compuesto que es farmacéuticamenteactivo, la N-(1,2,3,4-tetrahidro-5-metil-8-(4-metilpiperezin-1-il) -2-naftil)-4- morfolinbenzamida, que puede encontrarse como base libre, o como su sal farmacéuticamente aceptable. La invención también describe los procesos de preparación de dicha forma de dosificación, el uso de dicha forma de dosificación y un me´todo para prevenir y/o tratar trastornos de SNC y alteraciones me´dicas relacionadas usando dicha forma d dosificación.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0203778A SE0203778D0 (sv) | 2002-12-09 | 2002-12-09 | A new oral immediated release dosage form |
Publications (1)
Publication Number | Publication Date |
---|---|
UY28111A1 true UY28111A1 (es) | 2004-07-30 |
Family
ID=20289929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY28111A UY28111A1 (es) | 2002-12-09 | 2003-12-09 | Nueva forma de dosificación oral de liberación inmediata |
Country Status (9)
Country | Link |
---|---|
US (1) | US20060034911A1 (es) |
EP (1) | EP1572158A1 (es) |
JP (1) | JP2006510665A (es) |
AR (1) | AR042297A1 (es) |
AU (1) | AU2003283937A1 (es) |
SE (1) | SE0203778D0 (es) |
TW (1) | TW200502002A (es) |
UY (1) | UY28111A1 (es) |
WO (1) | WO2004052342A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080045548A1 (en) * | 2006-08-21 | 2008-02-21 | Astrazeneca Ab | Pharmaceutical Compositions |
TWI482772B (zh) * | 2006-08-21 | 2015-05-01 | Astrazeneca Ab | 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物 |
AU2018326596B2 (en) * | 2017-08-30 | 2021-07-08 | Prilenia Neurotherapeutics Ltd. | High concentration dosage forms of pridopidine |
KR102007499B1 (ko) * | 2017-09-11 | 2019-08-05 | 에이비온 주식회사 | 트리아졸로피라진계 화합물, 결합제 및 붕해제를 포함하는 속방형 캡슐제 조성물 |
TWI795462B (zh) | 2017-11-17 | 2023-03-11 | 日商鹽野義製藥股份有限公司 | 光安定性及溶出性優異的醫藥製劑 |
KR102659095B1 (ko) * | 2021-01-08 | 2024-04-19 | 에이비온 주식회사 | 트리아졸로피라진 유도체 화합물을 유효성분으로 하는 약학적 조성물의 태블릿정의 제조방법 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE204262T1 (de) * | 1991-09-18 | 2001-09-15 | Glaxo Group Ltd | Benzanilidderivate als 5-ht1d-antagonisten |
JPH10114655A (ja) * | 1996-10-09 | 1998-05-06 | Kyowa Hakko Kogyo Co Ltd | 固形製剤 |
SE9703375D0 (sv) * | 1997-09-18 | 1997-09-18 | Astra Ab | A new combination |
EP1974724A3 (en) * | 2000-09-22 | 2008-11-12 | Dainippon Sumitomo Pharma Co., Ltd. | Oral preparations with good disintegration |
WO2002036126A1 (en) * | 2000-10-30 | 2002-05-10 | Lupin Limited | Rapidly disintegrating sustained release cefuroxime axetil composition |
-
2002
- 2002-12-09 SE SE0203778A patent/SE0203778D0/xx unknown
-
2003
- 2003-12-04 AR ARP030104473A patent/AR042297A1/es unknown
- 2003-12-05 TW TW092134411A patent/TW200502002A/zh unknown
- 2003-12-08 WO PCT/SE2003/001910 patent/WO2004052342A1/en not_active Application Discontinuation
- 2003-12-08 US US10/537,858 patent/US20060034911A1/en not_active Abandoned
- 2003-12-08 EP EP03776159A patent/EP1572158A1/en not_active Withdrawn
- 2003-12-08 AU AU2003283937A patent/AU2003283937A1/en not_active Abandoned
- 2003-12-08 JP JP2004558963A patent/JP2006510665A/ja active Pending
- 2003-12-09 UY UY28111A patent/UY28111A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1572158A1 (en) | 2005-09-14 |
JP2006510665A (ja) | 2006-03-30 |
AU2003283937A1 (en) | 2004-06-30 |
WO2004052342A1 (en) | 2004-06-24 |
SE0203778D0 (sv) | 2002-12-09 |
US20060034911A1 (en) | 2006-02-16 |
TW200502002A (en) | 2005-01-16 |
AR042297A1 (es) | 2005-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20032233D0 (no) | Synergistiske foreninger som innbefatter en renininhibitor for kardiovaskul¶re sykdommer | |
BG108269A (en) | Pyrazolopyrimidines as therapeutic agents | |
BG108268A (en) | Pyrazolopyrimidines as therapeutic agents | |
TR200000129T2 (tr) | Yepyeni spiroazabisiklik heterosiklik bileşikler. | |
CO5690131A1 (es) | Derivados de eter biarilico que presentan actividad como inhibidores de la recaptacion de monoaminas para el tratamiento de transtornos del snc | |
ECSP045004A (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes | |
ECSP055525A (es) | Inhibidores de cinasas de tirosina | |
DK1296671T3 (da) | Gabapentinanaloger til sövnforstyrrelser | |
BR0306870A (pt) | Composição farmacêutica oral, e, método para preparar a mesma | |
ES2421948T3 (es) | Compuestos y composiciones para suministrar agentes activos | |
DE60312736D1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
HN2002000110A (es) | Uso de (z) - 2 - ciano - 3 - hidroxi - butil - 2 - acido enoico (4' - trifluorometil fenilo) - amida para el tratamiento de la esclerosis multiple. | |
CO5700723A2 (es) | Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca | |
RS51003B (sr) | Derivat piridin-1-oksida i postupak za njegovu transformaciju u farmaceutski efikasna jedinjenja | |
UY28111A1 (es) | Nueva forma de dosificación oral de liberación inmediata | |
NO20014855D0 (no) | N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister | |
AR029588A1 (es) | Nueva forma (r)-n-[5-metil-8-(4-metilpiperazina-1-il)-1,2,3,4-tetrahidro-2-naftil]-4-morfolinobenzamida | |
AR001765A1 (es) | Una formulación de liberación prolongada un procedimiento para su preparación una forma cristalina de cisaprida-(l)-tartrato y un medicamento util para el tratamiento de trastornos gastrointestinales | |
BR0207716A (pt) | Composto, formulação farmacêutica, e, método para a inibição de captação de norepinefrina e de serotonina em mamìferos | |
TW200507853A (en) | Use of s-10-hydroxy-10,11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders | |
ATE295845T1 (de) | Prucaloprid-n-oxid | |
GT200000087A (es) | Formas polimorfas de un citrato de azabiciclo(2.2.2) octan - 3 - amina y sus composiciones farmaceuticas. | |
HN2001000119A (es) | S-metil-dihidro -ziprasidona para el tratamiento de trastornos psiquiatricos y oculares. | |
ES2192608T3 (es) | Uso de derivados de alilamina tales como terbinafina, en la fabricacion de un medicamento para el tratamiento de la infeccion por helicobacter pylori de enfermedades asociadas. | |
TNSN99158A1 (ar) | طريقة لمنع الاصابة بالربو |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20150520 |